Skip to content
Screener

Glaukos GKOS Q1 2025 earnings

Reported April 30, 2025 · After market close

Revenue$106.7MBeat by $3.9M
EPS-$0.22Beat by $0.11
Revenue estimate$102.8M
EPS estimate-$0.33

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$167.9M
EPS estimate-$0.12

Financials

Q1 2025

Income statement

See full
Revenue$106.7M+24.6%
Gross profit$82.3M+26.0%
Operating income-$20.7M+47.1%
Net income-$18.1M+55.6%
EPS (diluted)-$0.32+61.0%

Balance sheet

See full
Cash & equivalents$114.3M+169%
Total debt$107.7M+4.9%
Total equity$764.0M+69.5%
Total assets$966.2M+3.5%

Cash flow

See full
Operating cash flow-$18.5M+45.3%
CapEx$1.9M+100%
Free cash flow-$20.5M+41.3%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$5.57B+19.4%
Enterprise value$5.56B+17.7%
P/S13.8×-0.5×

Profitability

See full
Gross margin75.8%-0.4pp
Operating margin-25.7%-7.0pp
Net margin-30.6%-6.9pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-20.4%-4.8pp
Debt / equity0.1×-0.1×
Current ratio6.5×+1.1×

Segments

By product

See full
Glaucoma$88.1M+31.1%
Corneal Health$18.5M+0.7%

By segment

See full
Development And Commercialization Of Ophthalmic Therapies$106.7M+24.6%

By geography

See full
US$75.1M—

FAQ

When did Glaukos report Q1 2025 earnings?
Glaukos (GKOS) reported Q1 2025 earnings on April 30, 2025 after market close.
What were Glaukos's Q1 2025 revenue and EPS?
Glaukos reported revenue of $106.7M and eps of $-0.22 for Q1 2025.
Did Glaukos beat estimates in Q1 2025?
Revenue beat the consensus estimate of $102.8M by $3.9M. EPS beat the consensus estimate of $-0.33 by $0.11.
How did Glaukos's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 24.6% from $85.6M a year earlier and eps grew 68.6% from $-0.70.
Where can I find Glaukos's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001558370-25-005999) and the 10-Q periodic report (0001558370-25-006041) directly on SEC EDGAR. The filing index links above go to sec.gov.